Literature DB >> 15869729

Dendritic cells in melanoma immunotherapy.

Mark B Faries1, Brian J Czerniecki.   

Abstract

No consensus exists regarding optimal systemic treatment for melanoma in the adjuvant or metastatic disease setting. Dendritic cell vaccine therapy, though investigational at present, offers very promising preliminary data that warrant exploration, and patients with existing disease and those seeking adjuvant treatment should evaluate open protocols using this strategy.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15869729     DOI： 10.1007/s11864-005-0001-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  35 in total

Review 1.  Exploiting dendritic cells to improve vaccine efficacy.

Authors:  Ralph M Steinman; Melissa Pope
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

2.  Characterization of cells prepared by dendritic cell-tumor cell fusion.

Authors:  Eva Gottfried; René Krieg; Christian Eichelberg; Reinhard Andreesen; Andreas Mackensen; Stefan W Krause
Journal:  Cancer Immun       Date:  2002-11-07

3.  Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.

Authors:  Shuwen Xu; Gary K Koski; Mark Faries; Isabelle Bedrosian; Rosemarie Mick; Markus Maeurer; Martin A Cheever; Peter A Cohen; Brian J Czerniecki
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

4.  Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro.

Authors:  Shikhar Mehrotra; Robert Stevens; Ryan Zengou; Nitya G Chakraborty; Lisa H Butterfield; James S Economou; David I Dorsky; Bijay Mukherji
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

5.  Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells.

Authors:  Gary K Koski; Katalin Karikó; Shuwen Xu; Drew Weissman; Peter A Cohen; Brian J Czerniecki
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

Review 6.  Processing and presentation of antigens by dendritic cells: implications for vaccines.

Authors:  N Bhardwaj
Journal:  Trends Mol Med       Date:  2001-09       Impact factor: 11.951

Review 7.  Immunodominance and tumor escape.

Authors:  H Schreiber; T H Wu; J Nachman; W M Kast
Journal:  Semin Cancer Biol       Date:  2002-02       Impact factor: 15.707

8.  Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.

Authors:  Mark Smithers; Kathleen O'Connell; Susan MacFadyen; Melita Chambers; Kathryn Greenwood; Amanda Boyce; Ibtissam Abdul-Jabbar; Kylie Barker; Karen Grimmett; Euan Walpole; Ranjeny Thomas
Journal:  Cancer Immunol Immunother       Date:  2002-11-13       Impact factor: 6.968

9.  Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses.

Authors:  Karin Loré; Michael R Betts; Jason M Brenchley; Janaki Kuruppu; Soorena Khojasteh; Stephen Perfetto; Mario Roederer; Robert A Seder; Richard A Koup
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

10.  Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function.

Authors:  Julie M Curtsinger; Debra C Lins; Matthew F Mescher
Journal:  J Exp Med       Date:  2003-05-05       Impact factor: 14.307
View more
  1 in total

Review 1.  Melanoma vaccines: mixed past, promising future.

Authors:  Junko Ozao-Choy; Delphine J Lee; Mark B Faries
Journal:  Surg Clin North Am       Date:  2014-08-07       Impact factor: 2.741
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.